LENZ Therapeutics, Inc. (NASDAQ:LENZ) Stock Has Consensus Target Price of $14.75 According to Brokerages

LENZ Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is mixed: Seven firms give LENZ a consensus “Hold” rating, with four buys, two holds and one sell; the average 12-month price target is $14.75.
  • LENZ reported a quarterly loss of $0.99 per share, missing estimates of $0.89, while revenue of $3.38 million also fell short of the $4.20 million forecast.
  • Major shareholder RA Capital sold 2.72 million shares for about $9.1 million, reducing its position by 97.93%. LENZ shares traded at $3.50 in Friday’s mid-day session.
  • Five stocks we like better than LENZ Therapeutics.

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have been assigned a consensus rating of "Hold" from the seven research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $14.75.

A number of equities research analysts have recently commented on the company. Zacks Research upgraded LENZ Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 13th. Weiss Ratings lowered LENZ Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, September 9th. Citigroup dropped their price target on LENZ Therapeutics from $10.00 to $9.00 and set a "buy" rating on the stock in a research note on Thursday. HC Wainwright cut their price objective on LENZ Therapeutics to $16.00 and set a "buy" rating on the stock in a report on Friday, October 30th. Finally, Piper Sandler reduced their price objective on shares of LENZ Therapeutics from $7.00 to $5.00 and set a "neutral" rating for the company in a research note on Monday, October 19th.

View Our Latest Analysis on LENZ

Insiders Place Their Bets

In related news, major shareholder Ra Capital Management, L.P. sold 2,718,684 shares of the stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $3.36, for a total value of $9,134,778.24. Following the completion of the sale, the insider directly owned 57,559 shares of the company's stock, valued at approximately $193,398.24. This represents a 97.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 8.30% of the company's stock.

Institutional Trading of LENZ Therapeutics

Several institutional investors have recently made changes to their positions in LENZ. BlackRock Inc. purchased a new stake in LENZ Therapeutics in the 2nd quarter worth approximately $13,019,000. Blue Owl Capital Holdings LP purchased a new stake in shares of LENZ Therapeutics during the second quarter worth $4,298,000. Primecap Management Co. CA acquired a new stake in LENZ Therapeutics during the second quarter valued at $2,682,000. Bank of America Corp DE boosted its position in LENZ Therapeutics by 377.4% during the first quarter. Bank of America Corp DE now owns 547,534 shares of the company's stock valued at $5,010,000 after purchasing an additional 432,846 shares during the last quarter. Finally, BML Capital Management LLC purchased a new position in LENZ Therapeutics in the third quarter valued at about $1,087,000. 54.32% of the stock is currently owned by institutional investors and hedge funds.

LENZ Therapeutics Price Performance

Shares of NASDAQ LENZ traded up $0.49 during mid-day trading on Friday, reaching $3.50. 785,586 shares of the company traded hands, compared to its average volume of 1,111,717. The firm has a market cap of $109.97 million, a PE ratio of -0.78 and a beta of 0.78. LENZ Therapeutics has a fifty-two week low of $2.80 and a fifty-two week high of $32.13. The stock has a fifty day simple moving average of $3.93 and a 200-day simple moving average of $7.73.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.10). LENZ Therapeutics had a negative return on equity of 56.10% and a negative net margin of 1,134.97%. The business had revenue of $3.38 million during the quarter, compared to analyst estimates of $4.20 million. As a group, analysts predict that LENZ Therapeutics will post -4.08 EPS for the current fiscal year.

About LENZ Therapeutics

(Get Free Report)

LENZ Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for the treatment of presbyopia, the age-related loss of near vision. The company is headquartered in San Diego, California, and its programs are designed to provide an alternative to reading glasses and other corrective lenses.

LENZ's primary product candidate is aceclidine ophthalmic solution, developed under the names LNZ100 and VIZZ. The pupil-selective miotic is intended to improve near vision while preserving distance vision, without relying on the lens-shaping mechanism targeted by some other presbyopia treatments.

Featured Articles

Analyst Recommendations for LENZ Therapeutics (NASDAQ:LENZ)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in LENZ Therapeutics Right Now?

Before you consider LENZ Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.

While LENZ Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines